Ultragenyx Pharmaceutical Inc. logo

RARE

Ultragenyx Pharmaceutical Inc.

$47.54

Earnings Summary

Revenue
$89.34Mn
Net Profits
$-158.16Mn
Net Profit Margins
-177.03%

Highlights

Revenue:

Ultragenyx Pharmaceutical Inc.’s revenue jumped 2.72% since last year same period to $89.34Mn in the Q2 2022. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 11.77% jump in its revenue since last 3-months.

Net Profits:

Ultragenyx Pharmaceutical Inc.’s net profit fell -29.19% since last year same period to $-158.16Mn in the Q2 2022. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated -3.84% fall in its net profits since last 3-months.

Net Profit Margins:

Ultragenyx Pharmaceutical Inc.’s net profit margin fell -25.76% since last year same period to -177.03% in the Q2 2022. On a quarterly growth basis, Ultragenyx Pharmaceutical Inc. has generated 7.1% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Ultragenyx Pharmaceutical Inc. post its latest quarter earnings

EPS Estimate Current Quarter
-1.3
EPS Estimate Current Year
-1.3

Highlights

EPS Estimate Current Quarter:

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current quarter stand at -1.3 - a 25.71% jump from last quarter’s estimates.

EPS Estimate Current Year:

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) estimates for the current year stand at -1.3.

Key Ratios

Key ratios of the Ultragenyx Pharmaceutical Inc. post its Q2 2022 earnings

Earning Per Share (EPS)
-2.26
Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.61
Dividend Per Share (DPS)
0

Highlights

Earning Per Share (EPS):

Ultragenyx Pharmaceutical Inc.’s earning per share (EPS) fell -24.86% since last year same period to -2.26 in the Q2 2022. This indicates that the Ultragenyx Pharmaceutical Inc. has generated -24.86% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Ultragenyx Pharmaceutical Inc.’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Ultragenyx Pharmaceutical Inc.’s return on equity (ROE) stands at -0.61.

Dividend Per Share (DPS):

Ultragenyx Pharmaceutical Inc. declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-07-29
-1.75
-2.26
-29.14%
2022-05-06
-1.76
-2.19
-24.43%

Company Information

Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.

Organisation
Ultragenyx Pharmaceutical Inc.
Headquarters
Novato, California, US
Employees
893
Industry
Health Technology
CEO
Emil Kakkis